Plant Name: Aglaia laxiflora
Taxonomic Information:
Plant ID: NPO6039
Plant Latin Name: Aglaia laxiflora
Taxonomy Genus: Aglaia
Taxonomy Family: Meliaceae
Plant External Links:
NCBI TaxonomyDB:
1475101
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| PTPN2; | |
| ALPL; RECQL; TDP1; P4HB; AKR1B1; HPGD; NOX4; APEX1; POLB; | |
| TEK; INSR; MET; KDR; EGFR; NUAK1; SRC; IGF1R; CSNK2A1; | |
| F10; | |
| RELA; NFKB1; | |
| SLC22A6; | |
| SMAD3; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | RELA | Nuclear factor NF-kappa-B p65 subunit | Q04206 | CHEMBL5533 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 1.868E-10 | 2.208E-07 | EGFR, IGF1R, INSR, KDR, MET, TEK |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 9.436E-10 | 6.804E-07 | EGFR, F10, INSR, MET, NOX4, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 4.337E-09 | 2.099E-06 | EGFR, IGF1R, INSR, KDR, SRC |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 5.156E-09 | 2.441E-06 | AKR1B1, CSNK2A1, EGFR, HSPA1A, IGF1R, KDR, NFKB1, RELA, SMAD3, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 2.596E-08 | 8.974E-06 | EGFR, INSR, KDR, NOX4, RELA, SMAD3, SRC |
| MF | Unclassified; | GO:0032403; protein complex binding | 3.845E-08 | 1.269E-05 | APEX1, EGFR, IGF1R, INSR, KDR, P4HB, PTPN2, RELA, SMAD3, SRC |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.809E-07 | 5.141E-05 | EGFR, INSR, KDR |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.327E-06 | 2.725E-04 | CSNK2A1, EGFR, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, RECQL, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.742E-06 | 3.387E-04 | APEX1, POLB |
| BP | GO:0050896; response to stimulus | GO:0071375; cellular response to peptide hormone stimulus | 2.225E-06 | 4.004E-04 | APEX1, INSR, NFKB1, RELA, SRC |
| BP | GO:0050896; response to stimulus | GO:0033590; response to cobalamin | 5.222E-06 | 7.897E-04 | EGFR, RELA |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 5.796E-06 | 8.542E-04 | EGFR, KDR, NOX4, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 5.841E-06 | 8.542E-04 | ALPL, APEX1, EGFR, NFKB1, NOX4, SRC |
| BP | GO:0050896; response to stimulus | GO:0051591; response to cAMP | 7.875E-06 | 1.114E-03 | APEX1, NOX4, RELA, TEK |
| BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 1.150E-05 | 1.473E-03 | INSR, PTPN2, SRC |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.611E-05 | 1.949E-03 | NFKB1, PTPN2, SMAD3, TEK |
| BP | GO:0008152; metabolic process | GO:2000630; positive regulation of miRNA metabolic process | 1.738E-05 | 2.068E-03 | NFKB1, RELA |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 1.780E-05 | 2.107E-03 | EGFR, HSPA1A, IGF1R, MET, NUAK1, P4HB, PTPN2 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 2.178E-05 | 2.510E-03 | NOX4, P4HB, SMAD3, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 2.231E-05 | 2.538E-03 | EGFR, INSR, SMAD3 |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 2.297E-05 | 2.591E-03 | AKR1B1, EGFR, GPR35, INSR, MET, NOX4, PTPN2, SMAD3 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.682E-05 | 2.950E-03 | CSNK2A1, EGFR, HPGD, IGF1R, KDR, MET, NFKB1, RELA, SLC22A6, SMAD3 |
| BP | GO:0032501; multicellular organismal process | GO:0045075; regulation of interleukin-12 biosynthetic process | 3.644E-05 | 3.725E-03 | NFKB1, RELA |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 3.644E-05 | 3.725E-03 | EGFR, POLB |
| CC | GO:0032991; macromolecular complex | GO:0033256; I-kappaB/NF-kappaB complex | 3.644E-05 | 3.725E-03 | NFKB1, RELA |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 4.489E-05 | 4.443E-03 | AKR1B1, APEX1, CSNK2A1, HPGD, HSPA1A, NFKB1, NUAK1, POLB, PTPN2, RECQL, RELA, SMAD3, SRC |
| BP | GO:0009987; cellular process | GO:0071316; cellular response to nicotine | 4.854E-05 | 4.719E-03 | NFKB1, RELA |
| BP | GO:0009987; cellular process | GO:1902532; negative regulation of intracellular signal transduction | 5.210E-05 | 4.933E-03 | HSPA1A, IGF1R, MET, PTPN2, RELA, SRC |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 5.422E-05 | 5.067E-03 | EGFR, IGF1R, INSR |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 7.398E-05 | 6.712E-03 | AKR1B1, APEX1, RELA |
| CC | Unclassified; | GO:0043234; protein complex | 7.598E-05 | 6.842E-03 | APEX1, CSNK2A1, EGFR, HSPA1A, IGF1R, INSR, NFKB1, P4HB, POLB, RELA, SLC22A6, SMAD3, SRC |
| MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 9.511E-05 | 8.251E-03 | IGF1R, INSR |
| BP | GO:0040011; locomotion | GO:0014910; regulation of smooth muscle cell migration | 9.795E-05 | 8.397E-03 | APEX1, NOX4, SRC |
| BP | GO:0009987; cellular process | GO:0051726; regulation of cell cycle | 1.035E-04 | 8.804E-03 | APEX1, CSNK2A1, EGFR, HPGD, HSPA1A, INSR, SMAD3, SRC |
| BP | GO:0051704; multi-organism process | GO:0035635; entry of bacterium into host cell | 1.140E-04 | 9.478E-03 | MET, SRC |
| CC | GO:0016020; membrane | GO:0005901; caveola | 1.164E-04 | 9.605E-03 | INSR, SLC22A6, SRC |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 4.413E-12 | 5.207E-10 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 3.190E-10 | 1.882E-08 | INSR, KDR, TEK, MET, RELA, EGFR, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 7.866E-09 | 1.856E-07 | INSR, KDR, TEK, MET, RELA, EGFR, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 7.306E-09 | 1.856E-07 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.410E-09 | 1.341E-07 | INSR, TEK, RELA, EGFR, NFKB1, IGF1R |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 3.003E-08 | 5.062E-07 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.435E-08 | 4.788E-07 | SRC, MET, RELA, EGFR, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.531E-06 | 2.258E-05 | SMAD3, RELA, EGFR, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 5.671E-06 | 5.577E-05 | SRC, KDR, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.082E-06 | 5.577E-05 | RELA, EGFR, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 9.687E-06 | 8.165E-05 | SMAD3, MET, EGFR, NFKB1, RELA, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 5.536E-06 | 5.577E-05 | SRC, KDR, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 3.152E-06 | 4.132E-05 | HPGD, MET, RELA, NFKB1, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 6.319E-06 | 5.736E-05 | INSR, RELA, NFKB1, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.595E-05 | 2.496E-04 | SMAD3, SRC, RELA, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.494E-05 | 1.962E-04 | SMAD3, INSR, EGFR, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 2.723E-05 | 2.008E-04 | CSNK2A1, RELA, NFKB1, HSPA1A |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 7.709E-05 | 4.538E-04 | INSR, HSPA1A, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.269E-04 | 5.988E-04 | CSNK2A1, RELA, NFKB1, HSPA1A |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.343E-04 | 6.094E-04 | POLB, SRC, RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 4.892E-05 | 3.207E-04 | RELA, NFKB1, HSPA1A |
| 09160 Human Diseases | 09162 Immune diseases | hsa05321 | Inflammatory bowel disease (IBD) | 8.075E-05 | 4.538E-04 | SMAD3, RELA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.051E-04 | 5.615E-04 | MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.096E-04 | 5.615E-04 | SRC, RELA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.142E-04 | 5.615E-04 | SMAD3, RELA, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.987E-04 | 1.200E-03 | SMAD3, RELA, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 3.094E-04 | 1.200E-03 | RELA, EGFR, NFKB1, HSPA1A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 8.075E-05 | 4.538E-04 | SRC, RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 3.234E-04 | 1.200E-03 | POLB, SMAD3, RELA, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 2.816E-04 | 1.187E-03 | SRC, EGFR, HSPA1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 2.342E-04 | 1.023E-03 | CSNK2A1, RELA, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 3.737E-04 | 1.336E-03 | INSR, RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 3.255E-04 | 1.200E-03 | SMAD3, RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 4.714E-04 | 1.636E-03 | RELA, NFKB1, HSPA1A |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 9.656E-04 | 3.080E-03 | INSR, RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 6.683E-04 | 2.253E-03 | RELA, EGFR, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 1.476E-03 | 4.467E-03 | RELA, NFKB1, HSPA1A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 1.550E-03 | 4.573E-03 | SRC, RELA, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 1.785E-03 | 5.015E-03 | SRC, RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 1.731E-03 | 4.982E-03 | CSNK2A1, RELA, NFKB1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 4.773E-03 | 9.881E-03 | KDR, MET, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 3.214E-03 | 7.740E-03 | EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 2.837E-03 | 7.123E-03 | SRC, KDR |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 4.035E-03 | 8.818E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.411E-03 | 8.051E-03 | MET, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.482E-03 | 6.367E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 4.035E-03 | 8.818E-03 | RELA, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 3.717E-03 | 8.435E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 4.593E-03 | 9.678E-03 | SRC, MET |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 2.482E-03 | 6.367E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.292E-03 | 4.011E-03 | SRC, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.916E-03 | 5.138E-03 | INSR, IGF1R |
| 09150 Organismal Systems | 09151 Immune system | hsa04622 | RIG-I-like receptor signaling pathway | 3.717E-03 | 8.435E-03 | RELA, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04623 | Cytosolic DNA-sensing pathway | 3.118E-03 | 7.665E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 4.254E-03 | 9.127E-03 | RELA, NFKB1 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 1.841E-03 | 5.051E-03 | RELA, NFKB1 |
| 09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 8.370E-04 | 2.744E-03 | POLB, APEX1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; EGFR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR; ALPL; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; IGF1R; KDR; TEK; EGFR; SRC; |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
| C00-D49: Neoplasms | AML | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; |
| I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; INSR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; EGFR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| NA: NA | Haemophilia B | NA | F10; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
| C00-D49: Neoplasms | Breast cancer | C50 | IGF1R; KDR; INSR; EGFR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| NA: NA | Christmas disease | NA | F10; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
| I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MET; IGF1R; KDR; CSNK2A1; NFKB1; TEK; EGFR; SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | IGF1R; INSR; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; EGFR; |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | EGFR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; F10; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
